Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel M Verbeek

Showing results (201-210 of 237) with videos related to

Pageof 24
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|August 16, 2021
Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral BloodJeannette Hübener-Schmid, Kirsten Kuhlbrodt, Julien Peladan, et al.
Circulation Research|January 19, 2018
Mutations in <i>CYB561</i> Causing a Novel Orthostatic Hypotension SyndromeMaarten P van den Berg, Rowida Almomani, Italo Biaggioni, et al.
Alzheimer'S Research & Therapy|April 23, 2024
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid AngiopathyIngeborg Rasing, Sabine Voigt, Emma A Koemans, et al.
Neurology|December 8, 2017
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosisEmily Feneberg, Patrick Oeckl, Petra Steinacker, et al.
Clinical Parkinsonism & Related Disorders|February 16, 2023
Time trends in demographic characteristics of participants and outcome measures in Parkinson's disease research: A 19-year single-center experienceBart R Maas, Bastiaan R Bloem, Yoav Ben-Shlomo, et al.
The Lancet. Haematology|June 4, 2026
Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort studyJosephus L M van Rooij, Peter H Wessels, Johanna M Niers, et al.
Clinical Chemistry and Laboratory Medicine|November 13, 2021
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluidJohan Gobom, Lucilla Parnetti, Pedro Rosa-Neto, et al.
Annals of Neurology|January 28, 2023
Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid AngiopathyAnna M De Kort, H Bea Kuiperij, Tainá M Marques, et al.
Journal of Inherited Metabolic Disease|September 11, 2022
Novel cerebrospinal fluid biomarkers of glucose transporter type 1 deficiency syndrome: Implications beyond the brain's energy deficitTessa M A Peters, Jona Merx, Pieter C Kooijman, et al.
Alzheimer'S Research & Therapy|April 6, 2024
Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathyKanishk Kaushik, Anna M de Kort, Rosemarie van Dort, et al.
Pageof 24

Showing results (201-210 of 237) with videos related to

Sort By:
Pageof 24
Movement Disorders : Official Journal of the Movement Disorder Society|August 16, 2021
Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral BloodJeannette Hübener-Schmid, Kirsten Kuhlbrodt, Julien Peladan, et al.
Circulation Research|January 19, 2018
Mutations in <i>CYB561</i> Causing a Novel Orthostatic Hypotension SyndromeMaarten P van den Berg, Rowida Almomani, Italo Biaggioni, et al.
Alzheimer'S Research & Therapy|April 23, 2024
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid AngiopathyIngeborg Rasing, Sabine Voigt, Emma A Koemans, et al.
Neurology|December 8, 2017
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosisEmily Feneberg, Patrick Oeckl, Petra Steinacker, et al.
Clinical Parkinsonism & Related Disorders|February 16, 2023
Time trends in demographic characteristics of participants and outcome measures in Parkinson's disease research: A 19-year single-center experienceBart R Maas, Bastiaan R Bloem, Yoav Ben-Shlomo, et al.
The Lancet. Haematology|June 4, 2026
Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort studyJosephus L M van Rooij, Peter H Wessels, Johanna M Niers, et al.
Clinical Chemistry and Laboratory Medicine|November 13, 2021
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluidJohan Gobom, Lucilla Parnetti, Pedro Rosa-Neto, et al.
Annals of Neurology|January 28, 2023
Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid AngiopathyAnna M De Kort, H Bea Kuiperij, Tainá M Marques, et al.
Journal of Inherited Metabolic Disease|September 11, 2022
Novel cerebrospinal fluid biomarkers of glucose transporter type 1 deficiency syndrome: Implications beyond the brain's energy deficitTessa M A Peters, Jona Merx, Pieter C Kooijman, et al.
Alzheimer'S Research & Therapy|April 6, 2024
Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathyKanishk Kaushik, Anna M de Kort, Rosemarie van Dort, et al.
Pageof 24